Hematology

Expert discusses the role of venetoclax in the treatment of AML and if achievement of MRD negativity can be used to predict long-term outcomes.

Expert continues discussion of IDH1 and IDH2 inhibitors in AML and examines prioritization of IDH1 and IDH2 inhibitors versus venetoclax in newly diagnosed AML.

Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy already indicated for B-cell precursor acute lymphoblastic leukemia and diffuse large B-cell lymphoma.

Alexandra S. Wolff, PharmD, BCOP, discusses use of IDH1 and IDH2 inhibitors in newly diagnosed AML patients and highlights recently released trial data.

Expert examines the status of second-generation FLT3 inhibitors in newly diagnosed AML patients and the challenge with comparing clinical trial efficacy endpoints.

Expert discusses the role of FLT3 inhibitors in the treatment of AML and if benefit from midostaurin in combination with chemotherapy can be predicted.

Between 40% and 50% of patients respond long term without relapsing.

Rivaroxaban is the first and only therapy indicated for both coronary artery disease and peripheral artery disease.

Rylaze was granted Fast Track Designation by the FDA in October 2019 for acute lymphoblastic leukemia and was approved as part of the Real-Time Oncology Review program.

When direct oral anticoagulants are taken, especially for the first time, patients may be at risk of bleeding.

The FDA has granted orphan drug designation to CFT7455 for the treatment of multiple myeloma, according to a press release from manufacturer C4 Therapeutics.

Physicians may ask for either or both of comprehensive metabolic panel or complete blood count tests every 3 to 6 months, based on the conditions patients have.

Daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen) was approved in July in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma following their first or subsequent relapse.

Polatuzumab vedotin regimen is the first in 2 decades to show such significant improvements.

Asparaginase erwinia chrysanthemi (recombinant)-rywn) (Rylaze) is approved for use as a component of a chemotherapy regimen for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma

MDM2 inhibitors and BET inhibitors, which show limited efficacy against acute myeloid leukemia (AML) as monotherapies, are potent against AML when used in combination, according to a study published in Nature Communications.

The American Cancer Society estimates that oncologists will diagnose about 34,920 new cases of multiple myeloma in 2021 with about 12,410 deaths expected to occur.

The open label trial was available to patients 18 years of age and older with relapsed or refractory DLBCL after 2 or more lines of treatment.

The research team noted that although HCL has a good prognosis for the majority of patients, a small population will develop variants of the disease do not respond well to existing FDA-approved therapies or cannot tolerate the adverse effects of established therapies.

Axicabtagene ciloleucel (Yescarta) received accelerated FDA approval on March 5, 2021, for the treatment of adult patients with relapsed or refractory FL after 2 or more lines of systemic therapy.

Aldosterone blockers, such as spironolactone and eplerenone, can cause hyperkalemia.

Venetoclax is already approved for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma, and in some adults with newly diagnosed acute myeloid leukemia.

Many HTCs use these drug pricing arrangements to reduce reliance on limited federal funding.

Zydelig (idelalisib) is a kinase inhibitor approved in 2014 for 3 oncology indications.

Trial identifies no new safety signals, as emicizumab continues to demonstrate effective bleeding control with a high proportion of participants achieving zero treated bleeds.

Heparin, a blood thinner given regularly at a low dose to hospitalized patients, helps to stop clots from forming and reduces inflammation.

Brexucabtagene autoleucel (Tecartus, Kite Pharma) is a cell-based gene therapy for the treatment of adult patients with mantle cell lymphoma who have not responded to or who have relapsed following other treatments.

The trial has successfully enrolled 17 patients with clear cell renal cell carcinoma and has reported that the drug is well tolerated at doses of up to 525 mg weekly.

Despite the encouraging progression-free survival findings, data on overall survival resulted in a partial clinical hold instituted by the FDA.

Results from the APOLLO trial showed a significant 37% reduction in the risk of progression or death, compared to pomalidomide and dexamethasone alone in patients with multiple myeloma.